Abstract
Objectives. A cost-effectiveness analysis was carried out comparing electrosurgical
transurethral resection of the prostate (TURP) with holmium:yttrium-aluminum-garnet
laser resection of the prostate (HoLRP).
Methods. One hundred twenty patients with benign prostatic hyperplasia and urodynamically
proved obstruction were randomized to undergo either TURP or HoLRP. Economic and clinical
outcome data were recorded prospectively out to 1 year postoperatively.
Results. The HoLRP group experienced fewer complications and had a shorter hospital
stay and catheterization time than the TURP group, with equivalent clinical outcomes
at 12 months. HoLRP cost 24.5% less (New Zealand dollars $651) than TURP during the
first year.
Conclusions. Because the clinical outcomes out to 1 year were equivalent, HoLRP was
more cost-effective than TURP. On the basis of these savings, a minimum of 93 cases
per year are required to recover the capital and service costs of the holmium:yttrium-aluminum-garnet
laser.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Introduction and concluding remarks.Eur Urol. 1999; 36: 1-6
- The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia.in: Dennis L Griffiths K Khoury S Proceedings of the Fourth International Consultation on Benign Prostatic Hyperplasia (BPH). Plymbridge Distributors, Plymouth1998: 61-81
- Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia.Urology. 1998; 51: 1-7
- Management of symptomatic BPH in France.Eur Urol. 1999; 36: 14-20
- Management of the BPH syndrome in Germany.Eur Urol. 1999; 36: 21-27
- Management of symptomatic BPH in Italy.Eur Urol. 1999; 36: 28-32
- Management of symptomatic BPH in the UK.Eur Urol. 1999; 36: 33-39
- The economics of benign prostatic hyperplasia treatment.Clin Ther. 1996; 18: 1227-1241
- Holmium laser resection of the prostate.Urology. 1996; 47: 48-51
- Holmium laser versus transurethral resection of the prostate.J Urol. 1999; 162: 1640-1644
- Cost-effectiveness analysis.J Endourol. 1998; 12: 485-491
- Holmium:YAG laser enucleation of the prostate combined with mechanical morcellation.Eur Urol. 1998; 33: 69-72
- Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation.J Endourol. 1998; 12: 457-459
Article info
Publication history
Accepted:
October 4,
2000
Received in revised form:
October 4,
2000
Received:
March 10,
2000
Footnotes
☆This study was partially funded by Coherent Medical Group. M. R. Fraundorfer and P. J. Gilling are study investigators who have received research funding from the sponsor of this study in the past.
Identification
Copyright
© 2001 Elsevier Science Inc. Published by Elsevier Inc. All rights reserved.